Gastrointestinal Carcinoid Tumor Survival Rate

The typical gastrointestinal carcinoid tumor is very slow growing, and the overall survival rate for the condition is good. In fact, recent information gathered from patients who had small, localized tumors that were surgically removed indicates that a complete cure may be possible in these cases. Of course, survival rates are based on the past outcomes of large numbers of people who had the condition several years ago, and no one can accurately predict what will happen in a particular patient’s case. For instance, carcinoid tumors can vary greatly in size, location and symptoms, and treatment should be individualized to ensure the best possible outcome.

The factors that are considered when determining the optimal course of treatment and survival rate for a patient with a gastrointestinal carcinoid tumor are multifaceted and complex. Key considerations include:

• The site of the tumor’s origin
• The size of the primary tumor
• The growth rate of the tumor
• The anatomical extent (spread) of the condition
• The type(s) of treatment used and the patient’s response
• The patient’s age and general health

At Moffitt Cancer Center, we believe there are good reasons to be hopeful about the gastrointestinal carcinoid tumor survival rate. We offer many advanced treatment options for carcinoid tumors, including the latest techniques in surgery, chemotherapy and radiation therapy. As a high-volume cancer center, Moffitt has experts who are experienced in diagnosing and treating this relatively rare condition. What’s more, a great deal of research is currently in progress through our promising clinical trials, which offer patients the ability to access effective therapy options that are shaping the future of treatment.

If you’d like to learn more about the gastrointestinal carcinoid tumor survival rate or discuss possible symptoms, such as abdominal pain, with an expert at Moffitt, call 1-888-663-3488 or complete a new patient registration form online. No referrals are required.